Drug Trial Radar · NCT05653284
A Study of AK130 in Patients With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Feb 9, 2023
Primary completion
Dec 12, 2023
Study completion May 30, 2024
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Dec 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AK130 (TIGIT/TGF-β bifunctional fusion protein) in patients with advanced malignant tumors.
Conditions
- Advanced Malignant Tumors
Interventions
AK130Drug
IV infusion, specified dose on specified days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of participants with adverse events (AEs)Time frame: From time ICF is signed until 90 days after last dose of AK130
- Number of participants with DLTsTime frame: During the first four weeks of treatment with AK130
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Cancer Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.